9LO7 image
Deposition Date 2025-01-22
Release Date 2025-03-26
Last Version Date 2025-04-09
Entry Detail
PDB ID:
9LO7
Keywords:
HYDROLASE
Title:
The crystal structure of PDE4D with 2317b
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Escherichia coli BL21
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.20 Å
R-Value Free:
0.29
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 21 21 21
9LO7 validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:3',5'-cyclic-AMP phosphodiesterase 4D
Gene (Uniprot):PDE4D
Chain IDs:A, B
Chain Length:506
Number of Molecules:2
Biological Source:Homo sapiens
UniProt ID:Q08499 Pfam ID:PF18100, PF00233 EC:3.1.4.53
Ligand Molecules
A1EKX
MG
ZN
Primary Citation
Structure-Based Optimization of Moracin M as Potent and Selective PDE4 Inhibitors with Antipsoriasis Effects.
J.Med.Chem. 68 6789 6803 (2025)
PMID: 40066994 DOI: 10.1021/acs.jmedchem.5c00266

Abstact

Psoriasis is a complex chronic inflammatory disease that severely affects the quality of life of patients. However, current medications could only control the symptoms but not cure psoriasis with unmet medical needs. Herein, structure-based optimizations of natural product moracin M (IC50 of 2.9 μM) led to a novel PDE4 inhibitor L30 with greatly improved potency (IC50 of 8.6 nM) and remarkable selectivity across other PDEs families (>201-fold). The binding pattern of L30 with PDE4 revealed by cocrystal structure was different from that of roflumilast. Besides, L30 could effectively inhibit the release of inflammatory cytokines and chemokines in Raw264.7 and HaCaT cell lines. Furthermore, topical administration of L30 exhibited significant therapeutic effects in an imiquimod-induced psoriasis mouse model. These findings highlighted the potential of PDE4 inhibitor L30 as a novel lead for the treatment of psoriasis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
9LO7